Dr Stuart McIntosh has 24 years medical and clinical development research experience with senior medical roles in biotech and large pharma at Aimmune, MedImmune/AstraZeneca and Takeda. Dr McIntosh has worked in both small molecule oncology and large molecule immune-oncology, including approved PD-L1 (durvalumab IMFINZI) and EGFR (gefitinib IRESSA) targeted therapies across all stages of development and marketing. Experience includes Global Medical Lead for phase III programs in lung and prostate cancer and pre and post marketing regulatory authority interactions and reporting in US, EU and Asia – including Japan and China. Prior to joining Carrick he was VP Clinical Development at Aimmune Therapeutics with responsibility for all European Clinical Science and Operations activities.
A UK trained physician Dr McIntosh qualified in 1995 and practiced in the UK and Australia becoming a Member of the Royal College of Surgeons of Edinburgh. Following time in academia gaining his research doctorate at the University of Newcastle he joined the pharmaceutical industry. He holds the Diploma of Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians London. He has completed higher medical training with entry on the General Medical Council Specialist Register under Pharmaceutical Medicine.